BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9547792)

  • 1. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
    Strand S; Galle PR
    Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
    Li-Weber M; Laur O; Dern K; Krammer PH
    Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
    Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
    J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
    Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
    J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
    Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
    Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.
    Oshimi Y; Oda S; Honda Y; Nagata S; Miyazaki S
    J Immunol; 1996 Oct; 157(7):2909-15. PubMed ID: 8816396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
    Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
    Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell cytotoxicity of human Schwann cells: TNFalpha promotes fasL-mediated apoptosis and IFN gamma perforin-mediated lysis.
    Bonetti B; Valdo P; Ossi G; De Toni L; Masotto B; Marconi S; Rizzuto N; Nardelli E; Moretto G
    Glia; 2003 Aug; 43(2):141-8. PubMed ID: 12838506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
    Williams NS; Engelhard VH
    J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The T cell death knell: immune-mediated tumor death in renal cell carcinoma.
    Uzzo RG; Kolenko V; Froelich CJ; Tannenbaum C; Molto L; Novick AC; Bander NH; Bukowski R; Finke JH
    Clin Cancer Res; 2001 Oct; 7(10):3276-81. PubMed ID: 11595725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
    Lewinsohn DM; Bement TT; Xu J; Lynch DH; Grabstein KH; Reed SG; Alderson MR
    J Immunol; 1998 Mar; 160(5):2374-9. PubMed ID: 9498779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control.
    Gerharz CD; Ramp U; Déjosez M; Mahotka C; Czarnotta B; Bretschneider U; Lorenz I; Müller M; Krammer PH; Gabbert HE
    Lab Invest; 1999 Dec; 79(12):1521-34. PubMed ID: 10616203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K; Bonardelle D; Bobé P; Kiger N
    Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling.
    Hargreaves RG; Borthwick NJ; Gilardini Montani MS; Piccolella E; Carmichael P; Lechler RI; Akbar AN; Lombardi G
    J Immunol; 1997 Apr; 158(7):3099-107. PubMed ID: 9120262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes.
    Sobek V; Balkow S; Körner H; Simon MM
    Eur J Immunol; 2002 Sep; 32(9):2490-9. PubMed ID: 12207333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis.
    Bachmann MF; Ohteki T; Faienza KM; Zakarian A; Kägi D; Speiser DE; Ohashi PS
    J Immunol; 1997 Nov; 159(9):4165-70. PubMed ID: 9379009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
    Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
    Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD95 ligand expression in dedifferentiated breast cancer.
    Müschen M; Moers C; Warskulat U; Niederacher D; Betz B; Even J; Lim A; Josien R; Beckmann MW; Häussinger D
    J Pathol; 1999 Nov; 189(3):378-86. PubMed ID: 10547600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.